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Available online xxxWe thank Prof Deeks for taking the time to read our study and
respond to our published manuscript [1]. He argues that “The high
sensitivity [of the study] is created by a flaw in the study design, as
has the low specificity”; that “Incomplete verification linked to the
result of the LFT” has led to the sensitivity being overestimated and
the specificity being underestimated; and that the 1525 patients with
“negative” LFT were “intentionally excluded from verification”.
We disagree that we have intentionally excluded the 1525
patients. Instead, we have clearly articulated in the manuscript that
we excluded 1525 patients from the analysis because these patients
were deemed not suspected of COVID-19 on the basis of both clinical
assessment and non-reactive LFT result. This was according to the
national protocol of the recommended use of LFT in symptomatic
patients across primary care in Austria.
Specifically, on 22nd October 2021, Austria published guidelines
recommending offer of LFT to symptomatic patients attending
healthcare settings, including primary care. Our paper (REAP2) evalu-
ates the pragmatic implementation of these guidelines across a large
primary care network of 20 general practices in the district of Liezen
[1]. The network was set up on recommendation of the initial study
(REAP1) evaluating RT-PCR testing in a single general practice [2] and
in preparation for a looming second COVID-19 wave in the autumn
2020. Payments for LFT testing to practices by sickness funds are per-
formance-linked and are stratified in three groups according to
COVID-19 risk using a combination of pre-test probability in clinical
triage and LFT result as per the following categories:
COVT1: High risk suspected COVID-19 AND reactive LFT,
COVT2: Not at risk of COVID-19 AND non-reactive LFT,DOI of original article: http://dx.doi.org/10.1016/j.eclinm.2021.101106.
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AND non-reactive LFT.
According to the national protocol, confirmatory RT-PCR testing
was required for COVT1 (referred to as Group 1 in REAP2) and
COVT3 (Group 2 in REAP2), but not for COVT2. The 1525 patients
excluded from the study are equivalent to COVT2 and not suspected
of COVID-19 due to clinical triage using a combination of clinical
assessment and non-reactive LFT. Therefore, under the national pro-
tocol, they were not RT-PCR tested. Hence, we re-iterate that the
exclusion of 1525 patients was on clinical grounds as per the
national protocol, but not “intentionally” to skew validation of data
as Prof Deeks suggests. We note that the aim of the work in REAP2
was to evaluate the accuracy of LFT in suspected patients for whom
RT-PCR was available and this included the 1027 patients (40% of
the total patients) studied.
Prof Deeks suggested that all 2562 patients, including 1027 sus-
pected cases (826 RT-PCR positive, 201 RT-PCR negative, 10 no RT-
PCR data) and 1525 not suspected cases, should have been included
in the analysis. Given the lack of RT-PCR data for the latter, he sug-
gested that, alternatively, the analysis should have been adjusted by
multiplying the LFT “negatives” by a factor of “eight” (1525/
217 = 7.0). However, doing this would have “overcounted” the num-
ber of negatives as it would have included patients unlikely to have
had COVID-19 (e.g., those presenting with food poisoning, glandular
fever, or bacterial tonsillitis, etc.). Given the combination of clinical
assessment and non-reactive LFT, patients in COVT2 can be assumed
to have very low pre-test probability when compared to moderate
(COVT2) and high risk (COVT1) suspected cases.
To estimate the percentage of patients not suspected of COVID-19
prior to LFT testing that may have tested RT-PCR positive if all 1525
patients were RT-PCR tested, we emailed all 20 participating general
practitioners (GPs) asking if any of the 1525 patients should have
been included. 15/20 GPs replied suggesting that a range of 110%
had the potential to be included if they were RT-PCR tested. Specifi-
cally, 4 practices suggested 1% of patients, 6 practices suggested
between 35%, 3 < 5% and 2 between 5 and 10%. Based on this,
although aware of a risk of potential recall bias, we would consider
these estimates as fairly accurate as all practices are single-handed
fostering a culture of close relationship between patients and their
doctor. Using this data, we undertook a sensitivity analysis on theer the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Table 1
Unadjusted accuracy (defined by sensitivity, specificity, positive predictive value and negative predictive value) of lateral flow testing (LFT) when compared to reverse tran-
scriptase-polymerase chain reaction (RT-PCR) on data from 1027 patients from a general practice network in Austria.
RT-PCR negative RT-PCR positive Total tests
LFT reactive 22 788 810 Positive Predictive Value 97.3%
LFT non-reactive 179 38 217 Negative Predictive Value
82.5%
Total tests 201 826 1027
Specificity 89.1% Sensitivity 95.4%
b. Estimated adjusted accuracy of LFT assuming 5% of patients clinically not suspected of COVID-19 that may have tested RT-PCR positive without LFT testing. This means
we need to redistribute the 76 (0.05£1525) patients into LFT non-reactive using the same ratio as before for RT-PCR positive and negative. As a result, sensitivity drops
slightly, and specificity increases slightly.
RT-PCR negative RT-PCR positive Total tests
LFT reactive 22 788 810 Positive Predictive Value 97.3%
LFT non-reactive 242 (= 179/217 £ 293) 51 (= 38/217 £ 293) 293 (= 217 + 76) Negative Predictive Value
82.6%
Total tests 264 839 1103 (1027 + 76)
Specificity 91.7% Sensitivity 93.9%
c. Estimated adjusted accuracy of LFT assuming 10% of patients clinically not suspected of COVID-19 that may have tested RT-PCR positive without LFT testing. This means
we need to redistribute the 153 (0.1 £ 1525) patients into LFT non-reactive using the same ratio as before for RT-PCR positive and negative. As a result, sensitivity drops
slightly, and specificity increases slightly.
RT-PCR negative RT-PCR positive Total tests
LFT reactive 22 788 810 Positive Predictive Value 97.3%
LFT non-reactive 305 (= 179/217 £ 370) 65 (= 38/217 £ 370) 370 (= 217 + 153) Negative Predictive Value
82.4%
Total tests 327 853 1180 (1027 + 153)
Specificity 93.3% Sensitivity 92.4%
2 W. Leber et al. / EClinicalMedicine 40 (2021) 101104accuracy adjusting for 5 and 10% reclassification i.e., addition to the
pool of LFT non-reactive from the pool of 1525 patients (see Table 1).
With these adjustments, sensitivity decreased slightly while specific-
ity increased slightly. Namely, assuming 5% reclassification, esti-
mated sensitivity was 93.9% and specificity was 91.7% while
assuming 10% reclassification, sensitivity was 92.4% and specificity
93.3%. We note that these estimates are only marginally different to
the sensitivity (95.4%) and specificity (89.1%) reported in the pub-
lished REAP2 paper. Clinical accuracy of a test varies according to dis-
ease prevalence. Sensitivity of a test increases with increased
prevalence, whilst its specificity decreases [3]. Therefore, the high
sensitivity and low specificity observed in our study likely are a func-
tion of high disease prevalence (positivity rate 79.7%) among sus-
pected cases undergoing clinical triage using both clinical assessment
and clinician-led testing during a major outbreak. In addition, the rel-
atively low specificity may represent faulty test kits, device storage
issues and difficulty in test interpretation when using five different
LFT products across 20 practices reporting initial data from the first 2
months of implementation.
We would also like to use this opportunity to clarify three aspects
around LFT testing. Firstly, we note that we referred to LFT results as
“reactive” and “non-reactive” rather than “positive” and “negative”
to account for the “preliminary” or “presumptive” nature of LFT untilconfirmed by RT-PCR. Secondly, performance of LFT widely varies
between healthcare and community settings, the mode of testing (cli-
nician-led vs. self-testing), and the health status of the individual
tested (asymptomatic/presymptomatic vs. symptomatic). Thirdly, we
agree with Prof Deeks that testing the patients not suspected with
COVID-19 with an RT-PCR test could have been an alternative way to
analyze the data. However, given the much lower pre-test probability
among this group, we would have analyzed this data separately from
the cohort of 1027 COVID-19 suspected cases.
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